Business Context and Reporting Period
Company: Alcon, Inc.
Filing Type: Form 20-F (Annual Report)
Period Covered: Fiscal year ended December 31, 2008
Jurisdiction: Incorporated in Switzerland; listed on the New York Stock Exchange (NYSE: ACL).
Business Overview: Alcon is a global medical specialty company focused on eye care, developing, manufacturing, and marketing pharmaceuticals, surgical equipment/devices, and consumer eye care products. The company operates through two segments: Alcon United States and Alcon International.
Key Financial Metrics (Year Ended Dec 31, 2008)
| Metric | 2008 (in millions) | 2007 (in millions) | Change |
|---|---|---|---|
| Sales | $6,294 | $5,600 | +12.4% |
| Gross Profit | $4,822 | $4,201 | +14.8% |
| Gross Margin | 76.6% | 75.0% | +160 bps |
| Operating Income | $2,213 | $1,883 | +17.5% |
| Net Earnings | $2,046 | $1,586 | +29.0% |
| Diluted EPS | $6.79 | $5.25 | +29.3% |
| Operating Cash Flow | $2,032 | $1,470 | +38.2% |
| Long-Term Debt | $61 | $52 | +17.3% |
| Total Shareholders' Equity | $4,691 | $3,375 | +38.9% |
Note: Sales growth included a 2.9% favorable impact from foreign exchange rates. Constant currency sales growth was 9.5%.
Material Changes vs. Prior Period
- Revenue Growth: Global sales increased 12.4% driven by volume growth (9.5% in constant currency) and favorable currency fluctuations. The acquisition of WaveLight AG contributed 1.2 percentage points to sales growth.
- Profitability: Net earnings rose 29.0% to $2.0 billion. This was significantly aided by a $235.7 million tax benefit related to the liquidation of a former subsidiary (Summit Autonomous) and a $15.2 million gain from a damages settlement. These were partially offset by $133.8 million in investment losses due to market conditions.
- Segment Performance:
- Alcon United States: Sales up 5.0% to $2.8 billion. Growth was driven by surgical products (AcrySof lenses) and consumer eye care, partially offset by contracting prescription markets and rebate program reinstatements.
- Alcon International: Sales up 19.1% (13.5% constant currency) to $3.5 billion. Growth was led by markets in Japan, China, Brazil, Spain, and Russia.
- Product Mix: Surgical sales grew 15.3%, driven by intraocular lenses and the WaveLight acquisition. Pharmaceutical sales grew 10.7%, with strong performance in glaucoma and anti-infectives.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
- Staffing Reduction: In February 2009, Alcon announced a reduction of approximately 260 positions, estimated to result in a $21 million pre-tax charge in Q1 2009, with expected annualized savings of $40 million.
- Dividend: The Board proposed a dividend of CHF 3.95 per share (approx. $3.38) for 2008, subject to shareholder approval in May 2009.
- Investment Strategy: Management liquidated holdings in hedge funds and REITs in late 2008 to reduce portfolio volatility, reinvesting proceeds into cash and fixed-income securities.
Key Risks and Contingencies
- Patent Expirations and Litigation:
- TobraDex: Exclusive marketing rights in the U.S. expired in January 2009, with generic versions launched immediately. Management expects a decline in sales and profits for this product.
- ANDA Litigation: Alcon is engaged in six patent infringement actions against generic manufacturers (Teva, Apotex, Barr, Sandoz) regarding products like Vigamox, Patanol, and Pataday. Outcomes could significantly impact future sales if patents are invalidated.
- Antitrust: Synergetics USA filed an antitrust lawsuit alleging monopoly power in vitreoretinal equipment; the Company believes claims are without merit.
- Ownership Structure: Nestlé owns approximately 52% of outstanding shares. Novartis owns approximately 25%. A Purchase and Option Agreement allows Novartis to purchase Nestlé's remaining shares between 2010 and 2011.
- Regulatory and Economic: Risks include reimbursement pressure from government payors (Medicare, EU, Japan), currency fluctuations, and the impact of the global economic crisis on elective surgical procedures.
Important Facts for Investor Verification
- TobraDex Generic Launch: Verify the actual impact on Q1 2009 revenue following the January 2009 expiration of exclusivity and the launch of generic competitors.
- Patent Litigation Outcomes: Monitor the status of the six ANDA lawsuits, particularly the Teva/Vigamox trial judgment expected in H1 2009, as a loss could accelerate generic competition.
- Investment Portfolio Losses: Review the composition of the investment portfolio and the extent of realized/unrealized losses ($133.8 million in 2008) to assess future volatility risks.
- Staffing Reduction Costs: Confirm the timing and magnitude of the $21 million restructuring charge announced in February 2009.
- Dividend Approval: Verify shareholder approval of the proposed CHF 3.95 dividend at the May 2009 Annual General Meeting.